CaryHealth’s Post

So much #truth here. Bringing you "The Seven Deadly Sins" [of #pharmacybenefitmanagement], courtesy of A. J. Loiacono. They include: 💰 𝗚𝗿𝗲𝗲𝗱, driven by profit from drug spend and maximized revenue at patients' expense 🦥 𝗦𝗹𝗼𝘁𝗵, where technological innovation has been ignored in favor of the status quo 😡 𝗪𝗿𝗮𝘁𝗵, where competition has been suppressed at all costs 💊 𝗚𝗹𝘂𝘁𝘁𝗼𝗻𝘆, when patients are steered toward #PBM-owned pharmacies, and patients are oversupplied You can see the others in the image below. Want to learn more about the importance of an aligned #PharmacyBenefitAdministration solution? Check out our blog on the subject here: https://okt.to/q9WPly

Wondering how to highlight your healthcare brand's latest clinical trial for a credible and positive outlook from #physicians? 🤔 🧩 Explore the right tool with Docplexus' Journal Watch – doctors go-to resource for crisp summaries of recent clinical trials. We focus on the essentials: rationale, design, key findings, and the study's significance. 📞Request a call back to learn more! 👉 https://bit.ly/47aGerh #Pharma #HealthcareMarketing #UserEngagement #DigitalHealthcare #Docplexus #ClinicalTrials

🚀 Unlock the full potential of your 340B Drug Program with SquareML.ai's advanced analytics solution! Gain insights into drug purchasing patterns, monitor inventory levels, ensure compliance, and identify cost-saving opportunities. Maximize patient care delivery and realize significant cost savings with data-driven decision-making. Empower your organization with SquareML.ai today!💊💡 For more information or to schedule a demo, please visit our website: SquareML.ai . #340BAnalytics #HealthcareInnovation #DataDrivenDecisionMaking #AIinHealthcare #MedicalImaging #HealthTech #HealthcareAI #RadiologyAI #DigitalHealth #HealthcareInnovation #AIforMedicine #HealthcareTechnology #ImagingAnalytics #AIAnalytics #RadiologySolutions #RSNA #ImageProcessing #ArtificialIntelligence #MachineLearning #SquareML #DiagnosticAccuracy #PatientCare

Great to see that behaviour change is becoming more recognised in our industry. We can only overcome habitual prescribing practices by changing the way we, as an industry, communicate. By building your narratives using the principles of behavioural science, we can help you communicate your data in a way that will pinpoint the barriers to change, and generate long-lasting, positive changes in behaviour.

During a session at the Outcomes® 2024 SYNC National Conference, Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed the impacts that advancements in #technology have had on #pharmacy. https://lnkd.in/e_yr7N_S #SYNC2024 #PharmacyNews Drug Topics Total Pharmacy

Long Shortz with LTR Pharma: Erectile dysfunction help just a spray away https://buff.ly/3yXPrIc #ASX #ASX200 $LTP LTR https://buff.ly/3ABkOZG

https://lnkd.in/ezBq-Ue7 Thrilled to see our sentiments echoed in this insightful article from @PME (PMLiVE.com) Network @PMLive (https://lnkd.in/edyxiHF5). At Alpharmaxim, we recognise the complexity of understanding and targeting behaviour change. Behaviours don't exist in isolation, and addressing them all simultaneously isn't feasible. That's why we advocate for small, incremental changes, which are more likely to succeed than sweeping transformations. Our behaviour change process centres on understanding and nudging healthcare professional (HCP) behaviour away from habitual prescribing patterns. By identifying barriers and leveraging behaviour science, we aim to empower HCPs to prescribe a wider range of medications based on evidence-based data, not just habit. We firmly believe that involving patients in healthcare interventions as early as possible is crucial. They play a pivotal role in influencing HCP prescribing behaviour, and by encouraging HCPs to embrace novel therapies earlier, we ensure that patients receive the right treatment at the right time. Together, we're shaping a more patient-centric healthcare landscape. #BehaviourChange #PME #Pharma

The potential of digital therapeutics (DTx) to change healthcare is huge, but are we ready? 🚀 With fragmented regulations and slow adoption by clinicians, the road to success isn’t easy. Ipsos has mapped out a five-stage framework focusing on patient engagement, regulatory hurdles, and earning stakeholder trust. To go “beyond the pill,” DTx needs to integrate smoothly into our healthcare system. 🏥 Are we prepared for a future where software stands alongside medication in our approach to patient care? 💊💻 #DigitalHealth #DTx #Pharma #HealthcareInnovation

PhRMA's Equity team partnered with NJI to create a virtual simulation that demonstrates the impact of social determinants on Americans’ health, illuminates inequities in the health care system, and generates thoughtful conversations about medication access among constituents. The interactive experience lets participants choose a personalized journey that simulates the patient experience of acquiring prescription medicines and culminates with a policy point and call to action. The exercise sheds light on the social and structural factors that prevent underserved communities from being able to access the prescriptions they need. © Pharmaceutical Research and Manufacturers of America 2023. All rights reserved. View the simulation at https://lnkd.in/eNK2yCcD. #virtualgame #immersivetech #interactiveexperience #healthcareinequities #socialdeterminantsofhealth